PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades.

Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.

The objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.

By reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.

For further information, please visit:
http://www.predictad.eu

Project co-ordinator:
Valtion teknillinen tutkimuskeskus VTT

Partners:

  • Nexstim Oy
  • Imperial College of Science, Technology and Medicine
  • Rigshospitalet
  • Kuopion yliopisto
  • Università degli Studi di Milano
  • GE Healthcare Ltd.
  • Uppsala universitet

Timetable: from 06/2008 – to 05/2011

Total cost: € 3.981.565

EC funding: € 2.891.526

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

C3-Cloud: the Digital Coordinated Care P…

Typically, when a patient is receiving care from GPs and Hospitals, these are normally uncoordinated and the patient is often presented with conflicting advice, or clinicians are required to assess...

Contact Tracing Apps Unlikely to Contain…

Contract tracing apps used to reduce the spread of COVID-19 are unlikely to be effective without proper uptake and support from concurrent control measures, finds a new study by UCL...

Philips Launches New Innovations to Help…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today presented new approaches to health and healthcare, and the shift to health-at-home, at its virtual consumer health...

Philips to Expand its Image-Guided Thera…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire Intact Vascular, Inc., a U.S.-based developer of medical...

Internet Searches for Anxiety Attacks Ta…

Many health experts are concerned that the COVID-19 pandemic could be having widespread effects on people's mental health, but assessing these concerns is difficult without data. "Traditional public health surveillance lacks...

Orion Health Secures Place on Emerging T…

Remote Patient Monitoring solution included on Crown Commercial Services Spark: Technology Innovation Marketplace. Healthcare organisations now have a simple route to procure personalised monitoring for people living with chronic conditions to...

Scientists Develop Low-Cost Chip to Dete…

Robust and widespread antibody testing has emerged as a key strategy in the fight against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. However current testing methods are too inaccurate...

Newly Merged CCG Expands Tech Support to…

Norfolk and Waveney Clinical Commissioning Group to support prescribers to improve the quality and safety of prescribing through deploying prescribing decision technology FDB OptimiseRx. A newly merged clinical commissioning group...

Anonymized Cell Phone Location Data can …

In March 2020, federal officials declared the COVID-19 outbreak a national emergency. Around the same time, most states implemented stay-at-home advisories - to different degrees and at different times. Publicly...

Designed Antiviral Proteins Inhibit SARS…

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19. The findings are reported today in Science. In the experiments, the lead...

Telehealth Scales Up During the Pandemic…

Hailed for its ability to erase distance between health care providers in cities and patients in rural areas, telehealth has ironically enabled medical care to continue in a time when...

Fitbit Receives Regulatory Clearance in …

Fitbit (NYSE:FIT) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as Conformité Européenne (CE) marking in the European Union, for its electrocardiogram (ECG) app...